Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBIT (2016 - 2026)

Gyre Therapeutics has reported EBIT over the past 16 years, most recently at -$8.3 million for Q4 2025.

  • Quarterly EBIT fell 1353.68% to -$8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 81.24% year-over-year, with the annual reading at $3.0 million for FY2025, 81.24% down from the prior year.
  • EBIT was -$8.3 million for Q4 2025 at Gyre Therapeutics, down from $6.9 million in the prior quarter.
  • Over five years, EBIT peaked at $51.5 million in Q2 2022 and troughed at -$91.6 million in Q4 2023.
  • The 5-year median for EBIT is $1.4 million (2024), against an average of -$6.3 million.
  • Year-over-year, EBIT soared 358.76% in 2022 and then tumbled 1353.68% in 2025.
  • A 5-year view of EBIT shows it stood at -$20.3 million in 2021, then dropped by 10.57% to -$22.5 million in 2022, then plummeted by 307.98% to -$91.6 million in 2023, then skyrocketed by 100.73% to $665000.0 in 2024, then tumbled by 1353.68% to -$8.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBIT are -$8.3 million (Q4 2025), $6.9 million (Q3 2025), and $2.2 million (Q2 2025).